Developer docs
API playgroundTry for free, no card

Search company profiles

KdT Ventures

Full company profile

uuid0000dwt

Namestring
KdT Ventures
Legal namestring
KdT Ventures LLC
Websiteurl
kdtvc.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

KdT Ventures is an early-stage venture capital firm founded in 2017 and headquartered in Austin, Texas, that backs founders engineering the future at what it describes as the deepest layer of science—from atoms to bits. The firm's investment thesis is built on the premise that "science is the source code of reality," targeting companies commercializing frontier advances across biology, chemistry, physics, and computation. KdT typically acts as the first institutional check into a company, leading or co-leading pre-seed and seed rounds, with a model explicitly designed for high-uncertainty, high-technical-risk beginnings where great science becomes a venture-scale business.

The firm operates a single integrated investment service rather than a multi-product platform, with portfolio breadth spanning life sciences, digital health, frontier technology, and industrials (57 portfolio companies across sectors such as biotech, oncology, RNA therapeutics, AI-enabled drug discovery, carbon-negative manufacturing, and clinical AI). Revenue mechanics follow standard VC economics: management fees on committed capital under management (typically ~2% annually) plus carried interest (typically ~20% above hurdle) from successful exits, with direct equity ownership in portfolio companies across stages from pre-seed through IPO. The firm is led by Managing Partners Cain McClary (Founder), Mack Healy, and Phil Grayeski, with additional Partner, Principal, Associate, Head of Operations, and Head of Talent roles on an 8-person core team. Portfolio company partnerships with Bristol Myers Squibb, NVIDIA, Sanofi, Mubadala, Bayer/Vividion, and Ginkgo Bioworks illustrate the downstream validation and exit pathways accessible through KdT's network.

Short descriptiontext

KdT Ventures is an Austin-based early-stage venture capital firm founded in 2017 that leads or co-leads pre-seed and seed rounds in frontier science companies spanning biology, chemistry, physics, and computation. The firm typically acts as the first institutional check, backing 57 portfolio companies with $100M+ raised as of late 2024.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAustin, United States
HQ citystring
Austin
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital investing, early-stage funding, frontier science, seed investing, deep tech investment
Industry2 codes
PRIMARYFSANAAAA
Early-Stage Venture Capital (Pre-Seed/Seed)
SECONDARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
NAICS code2 codes
  • All Other Financial Investment Activities52399
  • Portfolio Management and Investment Advice523940
Product category
Venture Capital
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Fund management fees
TypeSubscription Recurring
Description

Traditional VC management fee structure charged on committed capital under management, typically 2% of AUM annually.

kdtvc.com
2Carried interest (carry)
TypeLicensing Royalties
Description

Performance fee of typically 20% of profits above the hurdle rate from successful portfolio company exits, representing the primary economic upside for the GP.

kdtvc.com
3Portfolio company equity
TypeTransaction Fee
Description

Direct equity ownership in portfolio companies through pre-seed, seed, Series A, B, and C investments, with returns realized through exits or IPOs.

kdtvc.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

KdT Ventures is an early-stage venture capital firm that provides pre-seed and seed investment capital to science-based founders. The firm typically acts as the first institutional check into companies, leading or co-leading rounds for startups commercializing frontier science across biology, chemistry, physics, and computation. Its investment model targets high-uncertainty beginnings where deep science becomes a venture-scale business.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Over $100M raised for early-stage investments
+2 more records
Product overview1 text field

KdT Ventures operates as a venture capital firm offering a single unified investment service rather than a platform-plus-modules architecture. The firm specializes in backing founders engineering frontier science at the deepest layer, from atoms to bits, with a focus on the physical layer of medicine, chemicals, and materials. Their investment model is built for high-uncertainty beginnings where great science becomes a venture-scale business, typically being the first institutional investor and leading or co-leading pre-seed and seed rounds. The company also maintains a portfolio job board platform for talent recruitment across their invested companies.

Product and service2 records
1Early-Stage Frontier Science Investing
CategoryVenture Capital
2Portfolio Job Board
CategoryTalent Platform
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-19
Description

NGM Bio and KdT Ventures entered into a worldwide license agreement for NGM313, a Phase 2-ready FGFR1c/β-Klotho agonist drug candidate. This represents a direct investment and co-development partnership between NGM Bio and KdT Ventures.

2Bristol Myers Squibb
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-12-14
Description

Terray Therapeutics, a KdT portfolio company, announced a multi-target collaboration with Bristol Myers Squibb for drug discovery, demonstrating Terray's platform capabilities being validated by a major pharmaceutical partner.

kdtvc.com
Strategic tierMajorTypeTechnology or IntegrationAnnounced on2023-11-09
Description

Terray Therapeutics announced investment from NVIDIA to enable generative AI design for drug discovery, bringing compute infrastructure and AI capabilities to enhance Terray's spatially encoded screening platform.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-10-06
Description

Ginkgo Bioworks acquired Circularis, a KdT portfolio company, demonstrating successful exit and strategic acquisition of a portfolio company by a major synthetic biology player.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Bayer's Vividion subsidiary was reported to be pursuing up to nine oncology targets from a Duke spinout, with KdT Ventures associated with this ecosystem of biotech-pharma collaborations.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Lux Capital is a US-based venture firm investing in frontier science and technology at the earliest stages, with a comparable 'atoms to bits' mandate spanning biotech, advanced materials, and deep tech — directly overlapping with KdT's portfolio focus.

TypeDirect peer
Description

ARCH is a pioneer in early-stage science venture capital, founding and seeding biotech, advanced materials, and physical-science companies — directly comparable to KdT's approach of leading pre-seed/seed rounds into frontier science.

TypeDirect peer
Description

DCVC invests in early-stage companies applying deep computing and engineering to science, including biotech, materials, and energy — closely matching KdT's combination of computation and physical-layer thesis.

TypeDirect peer
Description

Prime Movers Lab backs early-stage frontier science startups reinventing energy, transportation, infrastructure, and human health — directly comparable to KdT's pre-seed/seed focus on engineering the physical layer.

TypeDirect peer
Description

Section 32 is a science-focused venture fund investing at the intersection of biology, computation, and technology — closely matching KdT's frontier science and early-stage mandate.

TypeDirect peer
Description

Breakout Ventures is an early-stage fund investing in frontier science and technology companies commercializing breakthroughs in biology, materials, and energy — directly aligned with KdT's pre-seed/seed model.

TypeDirect peer
Description

Fifty Years is an early-stage venture fund backing founders solving the world's biggest problems through deep tech and science — overlapping with KdT's high-uncertainty, mission-driven investing approach.

TypeDirect peer
Description

Obvious Ventures invests in early-stage science-driven companies across health, energy, and sustainable production — comparable in stage and thematic focus to KdT Ventures.

TypeDirect peer
Description

Artis Ventures invests early in companies leveraging frontier science and technology across healthcare, energy, and materials — directly comparable to KdT's frontier-physical-layer mandate.

TypeBroad incumbent
Description

Andreessen Horowitz's Bio fund invests across biotech and digital health at scale — overlapping with KdT's portfolio (e.g., co-investor activity in biotech rounds) but as part of a much larger, multi-stage generalist platform rather than a focused frontier-science thesis.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment90 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

KdT Ventures

Venture Capitalkdtvc.com

KdT Ventures is an Austin-based early-stage venture capital firm founded in 2017 that leads or co-leads pre-seed and seed rounds in frontier science companies spanning biology, chemistry, physics, and computation. The firm typically acts as the first institutional check, backing 57 portfolio companies with $100M+ raised as of late 2024.

What KdT Ventures does

KdT Ventures is an early-stage venture capital firm founded in 2017 and headquartered in Austin, Texas, that backs founders engineering the future at what it describes as the deepest layer of science—from atoms to bits. The firm's investment thesis is built on the premise that "science is the source code of reality," targeting companies commercializing frontier advances across biology, chemistry, physics, and computation. KdT typically acts as the first institutional check into a company, leading or co-leading pre-seed and seed rounds, with a model explicitly designed for high-uncertainty, high-technical-risk beginnings where great science becomes a venture-scale business.

The firm operates a single integrated investment service rather than a multi-product platform, with portfolio breadth spanning life sciences, digital health, frontier technology, and industrials (57 portfolio companies across sectors such as biotech, oncology, RNA therapeutics, AI-enabled drug discovery, carbon-negative manufacturing, and clinical AI). Revenue mechanics follow standard VC economics: management fees on committed capital under management (typically ~2% annually) plus carried interest (typically ~20% above hurdle) from successful exits, with direct equity ownership in portfolio companies across stages from pre-seed through IPO. The firm is led by Managing Partners Cain McClary (Founder), Mack Healy, and Phil Grayeski, with additional Partner, Principal, Associate, Head of Operations, and Head of Talent roles on an 8-person core team. Portfolio company partnerships with Bristol Myers Squibb, NVIDIA, Sanofi, Mubadala, Bayer/Vividion, and Ginkgo Bioworks illustrate the downstream validation and exit pathways accessible through KdT's network.

KdT Ventures firmographics

Firmographics
Name
KdT Ventures
Legal name
KdT Ventures LLC
Website
https://kdtvc.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
KdT Ventures is an Austin-based early-stage venture capital firm founded in 2017 that leads or co-leads pre-seed and seed rounds in frontier science companies spanning biology, chemistry, physics, and computation. The firm typically acts as the first institutional check, backing 57 portfolio companies with $100M+ raised as of late 2024.
Ownership category
akta.pro rank

KdT Ventures industry classification

Industry
Product category
Venture Capital
NAICS
All Other Financial Investment Activities (52399), Portfolio Management and Investment Advice (523940)
akta.pro industry
PRIMARYFSANAAAA
Early-Stage Venture Capital (Pre-Seed/Seed)
SECONDARYFSANAAAB
Early-Stage Venture Capital (Series A/B)

Keywords

  • Venture capital investing
  • Early-stage funding
  • Frontier science
  • Seed investing
  • Deep tech investment

Where KdT Ventures is headquartered

Location

Headquarters

HQ city
Austin
HQ country
United States
HQ region
North America

Offices1 record

Markets served

KdT Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Fund management fees: Traditional VC management fee structure charged on committed capital under management, typically 2% of AUM annually.
  2. Carried interest (carry): Performance fee of typically 20% of profits above the hurdle rate from successful portfolio company exits, representing the primary economic upside for the GP.
  3. Portfolio company equity: Direct equity ownership in portfolio companies through pre-seed, seed, Series A, B, and C investments, with returns realized through exits or IPOs.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

KdT Ventures product offering

Product offering

Core offering

KdT Ventures is an early-stage venture capital firm that provides pre-seed and seed investment capital to science-based founders. The firm typically acts as the first institutional check into companies, leading or co-leading rounds for startups commercializing frontier science across biology, chemistry, physics, and computation. Its investment model targets high-uncertainty beginnings where deep science becomes a venture-scale business.

Product overview

KdT Ventures operates as a venture capital firm offering a single unified investment service rather than a platform-plus-modules architecture. The firm specializes in backing founders engineering frontier science at the deepest layer, from atoms to bits, with a focus on the physical layer of medicine, chemicals, and materials. Their investment model is built for high-uncertainty beginnings where great science becomes a venture-scale business, typically being the first institutional investor and leading or co-leading pre-seed and seed rounds. The company also maintains a portfolio job board platform for talent recruitment across their invested companies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Early-Stage Frontier Science Investing
  • Portfolio Job Board

Quantifiable outcome

  • Over $100M raised for early-stage investments
  • +2 more outcomes

Companies that use KdT Ventures

Customer profile

Named customers8 records

Segments1 record

Ideal customer profiles1 record

KdT Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

KdT Ventures partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and major.

  • NGM BiocoreStrategic or Co-development Partner · 19 December 2024NGM Bio and KdT Ventures entered into a worldwide license agreement for NGM313, a Phase 2-ready FGFR1c/β-Klotho agonist drug candidate. This represents a direct investment and co-development partnership between NGM Bio and KdT Ventures.
  • Bristol Myers SquibbcoreStrategic or Co-development Partner · 14 December 2023Terray Therapeutics, a KdT portfolio company, announced a multi-target collaboration with Bristol Myers Squibb for drug discovery, demonstrating Terray's platform capabilities being validated by a major pharmaceutical partner.
  • NVIDIAmajorTechnology or Integration · 9 November 2023Terray Therapeutics announced investment from NVIDIA to enable generative AI design for drug discovery, bringing compute infrastructure and AI capabilities to enhance Terray's spatially encoded screening platform.
  • Ginkgo BioworksmajorStrategic or Co-development Partner · 6 October 2022Ginkgo Bioworks acquired Circularis, a KdT portfolio company, demonstrating successful exit and strategic acquisition of a portfolio company by a major synthetic biology player.
  • Bayer (via Vividion)majorStrategic or Co-development PartnerBayer's Vividion subsidiary was reported to be pursuing up to nine oncology targets from a Duke spinout, with KdT Ventures associated with this ecosystem of biotech-pharma collaborations.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

KdT Ventures competitors and assessment

Company assessment

Direct peers

  • Lux Capital: Lux Capital is a US-based venture firm investing in frontier science and technology at the earliest stages, with a comparable 'atoms to bits' mandate spanning biotech, advanced materials, and deep tech — directly overlapping with KdT's portfolio focus.
  • ARCH Venture Partners: ARCH is a pioneer in early-stage science venture capital, founding and seeding biotech, advanced materials, and physical-science companies — directly comparable to KdT's approach of leading pre-seed/seed rounds into frontier science.
  • DCVC (Data Collective): DCVC invests in early-stage companies applying deep computing and engineering to science, including biotech, materials, and energy — closely matching KdT's combination of computation and physical-layer thesis.
  • Prime Movers Lab: Prime Movers Lab backs early-stage frontier science startups reinventing energy, transportation, infrastructure, and human health — directly comparable to KdT's pre-seed/seed focus on engineering the physical layer.
  • Section 32: Section 32 is a science-focused venture fund investing at the intersection of biology, computation, and technology — closely matching KdT's frontier science and early-stage mandate.
  • Breakout Ventures: Breakout Ventures is an early-stage fund investing in frontier science and technology companies commercializing breakthroughs in biology, materials, and energy — directly aligned with KdT's pre-seed/seed model.
  • Fifty Years: Fifty Years is an early-stage venture fund backing founders solving the world's biggest problems through deep tech and science — overlapping with KdT's high-uncertainty, mission-driven investing approach.
  • Obvious Ventures: Obvious Ventures invests in early-stage science-driven companies across health, energy, and sustainable production — comparable in stage and thematic focus to KdT Ventures.
  • Artis Ventures: Artis Ventures invests early in companies leveraging frontier science and technology across healthcare, energy, and materials — directly comparable to KdT's frontier-physical-layer mandate.

Broad incumbents

  • Andreessen Horowitz (a16z Bio): Andreessen Horowitz's Bio fund invests across biotech and digital health at scale — overlapping with KdT's portfolio (e.g., co-investor activity in biotech rounds) but as part of a much larger, multi-stage generalist platform rather than a focused frontier-science thesis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

KdT Ventures social profiles

Digital presence

KdT Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

KdT Ventures leadership team

Management profile

Number of profiles

Profiles8 records

KdT Ventures funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

KdT Ventures M&A and investment

M&A and investment

M&A

Investments90 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about KdT Ventures

What does KdT Ventures do?

KdT Ventures is an early-stage venture capital firm that provides pre-seed and seed investment capital to science-based founders. The firm typically acts as the first institutional check into companies, leading or co-leading rounds for startups commercializing frontier science across biology, chemistry, physics, and computation. Its investment model targets high-uncertainty beginnings where deep science becomes a venture-scale business.

Is KdT Ventures a public or private company?

KdT Ventures is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was KdT Ventures founded?

KdT Ventures was founded in 2017. It employs 11 to 50 people.

Where is KdT Ventures based?

KdT Ventures is headquartered in Austin, United States, in the North America region.

How does KdT Ventures make money?

Three revenue lines are on record. Fund management fees are the primary driver. The others are carried interest (carry) and portfolio company equity.

Who are KdT Ventures's main competitors?

Direct peers on record are Lux Capital, ARCH Venture Partners, DCVC (Data Collective), Prime Movers Lab, Section 32, Breakout Ventures, Fifty Years, Obvious Ventures and Artis Ventures. Andreessen Horowitz (a16z Bio) is listed as a broad incumbent.

Does KdT Ventures have an API?

No public API is recorded for KdT Ventures.

What industry is KdT Ventures in?

KdT Ventures's product category is Venture Capital. Its primary akta.pro industry code is FSANAAAA, Early-Stage Venture Capital (Pre-Seed/Seed), with a secondary code of FSANAAAB, Early-Stage Venture Capital (Series A/B). Its NAICS code is 52399.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireNGM Bio and KdT Ventures Enter into Worldwide License Agreement for NGM313, a Phase 2-ready FGFR1c/β-Klotho Agonist Drug CandidateNGM Bio and KdT Ventures signed a worldwide license agreement for NGM313, a Phase 2-ready FGFR1c/β-Klotho agonist. NGM Bio will receive up to $608 million in milestones and royalties, plus equity in a new company. KdT will develop NGM313 in a rare disease, with a Phase 2 study planned for 2025.Pulse 2.0KdT Ventures: Fund IV Closed At Over $100 MillionKdT Ventures closed its oversubscribed fourth fund, raising over $100 million, its largest to date. The firm's total assets under management now exceed $250 million, and it will focus on early-stage science-driven companies. The announcement also includes promotions of Phil Grayeski and Patrick Malone.FinSMEsKdT Ventures Closes Fourth Fund, at over $100MKdT Ventures closed its fourth fund at over $100 million, its largest to date. The fund follows the firm's $80 million Fund III from 2022, and total assets under management now exceed $250 million.American City Business JournalsAustin venture capital firm KdT Ventures raises $100M fund to back science-driven startupsAustin-based KdT Ventures closed its fourth fund with over $100 million, its largest to date, up from $80 million in the third fund. The firm, founded in 2017, invests in science-driven startups, with most portfolio companies in digital health and therapeutics. It also sees potential in AI-powered companies that have data acquisition advantages.FinSMEsKdT Ventures Closes Fund II, at $50MKdT Ventures closed its second fund at $50M, focusing on gene and biological circuit fabrication, delivery technologies, biomaterials, and consumer biology. The firm has already deployed capital in Elegen, Xilis, STRM, Abridge, Dimension Inx, and Andes. The Austin-based VC was founded in 2017 and previously deployed $15M in its inaugural fund.TechCrunchPlanting seed investments on tech’s frontiers nets KdT Ventures $50 million for its latest fundKdT Ventures has closed an oversubscribed $50 million fund to invest in startups focused on the intersection of software and life sciences. The firm, co-founded by Cain McClary and Mack Healy, previously managed a $15 million fund that included investments in companies such as Solugen, PathAI, and Dyno Therapeutics. KdT is headquartered in Austin, Texas, with additional scouting operations in Houston and North Carolina.FinSMEsDebut Biotechnology Raises $2.6M in Seed FundingDebut Biotechnology, a UC-Irvine spinout, closed a $2.6M seed round led by KdT Ventures. The funding will support integrations, business development, doubling the science team, and creating a pilot production system. The company partners with two large manufacturers to integrate its cell-free platform.FinSMEsAzitra Raises $14M in Series A FinancingAzitra Inc. closed a $14M Series A financing led by KdT Ventures, bringing total funding to $17M. The funds will expand its management team and advance medical dermatology products for conditions like cancer therapy-associated skin rashes and atopic dermatitis.PR NewswireKdT Ventures Closes Oversubscribed Inaugural FundKdT Ventures, an early-stage venture capital firm investing in frontier computational science and life sciences, has announced the successful close of its inaugural fund with participation from institutional investment firms and technology and life science industry leaders. The fund targets pre-Seed and Seed stage deals with capacity to follow-on through Series A and beyond, and was founded by Cain McClary MD after a career as a physician, start-up operator, and angel investor. The firm has disclosed a portfolio that includes PathAI, Solugen, Checkerspot, Azitra, Patch'd, Hi Fidelity Genetics, and Elemental Machines.FinSMEsAzitra Secures $2.15M Convertible Debt FinancingAzitra Inc. secured $2.15M in convertible debt financing led by Connecticut Innovations, with Bios Partners and KdT Ventures joining. The funding brings total raised to $5.4M, to be used for advancing its dermatology pipeline ahead of first-in-human testing this year.